乳腺癌放疗后急性冠脉综合征的预后
该研究纳入1970-2009年治疗的398例早期乳腺癌后发生ACS的患者,比较接受与未接受内乳链(IMC)照射者的ACS预后。IMC照射组心脏死亡十年累积风险35%(95%CI 29-41),未照射组24%(95%CI 17-31),校正混杂后IMC照射与更差预后相关(心脏死亡HR=1.7,95%CI 1.1-2.5)。提示心脏高剂量放疗可能加重ACS预后。
要点
- 乳腺癌放疗后发生ACS者,IMC照射组心脏死亡十年累积风险35%,未照射组24%。
- 校正混杂因素后,IMC照射与心脏死亡风险升高相关(HR=1.7,95%CI 1.1-2.5)。
- 心脏高剂量放疗可能加重后续ACS预后,或影响乳腺癌幸存者ACS风险管理。
核心结论
- 心脏受照剂量较高时,放疗可能加重乳腺癌患者后续急性冠脉综合征的预后。
研究设计与样本
- 基于医院队列的回顾性研究,纳入1970-2009年治疗的398例年龄<71岁早期乳腺癌后发生ACS的患者。
- 通过向全科医生和心脏科医生发放问卷获取心血管疾病发病和死因,比较接受与未接受IMC照射者的ACS预后。
- 采用多变量Cox比例风险模型和累积发病率评估ACS预后。
主要发现
- 398例ACS患者中62%接受过IMC照射,38%未接受,ACS诊断中位年龄67岁,乳腺癌至ACS中位间隔15年。
- ACS后十年心脏死亡累积风险在IMC照射组为35%(95%CI 29-41),未照射组为24%(95%CI 17-31),p=0.04。
- 校正混杂因素后,IMC照射与更差ACS预后相关,心脏死亡风险比HR=1.7(95%CI 1.1-2.5)。
临床怎么用
- 对乳腺癌放疗后发生ACS的幸存者,应结合既往心脏受照剂量(如是否接受IMC照射)评估预后风险。
- 该发现可能支持将心脏高剂量放疗史纳入乳腺癌幸存者ACS后的风险分层管理。
局限性
- 原文未报告本研究的具体局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Breast cancer patients treated with radiotherapy are at increased risk of subsequent acute coronary syndromes (ACS). We aimed to study if radiotherapy also influences the prognosis of these ACS. MATERIALS AND METHODS: We included all 398 patients diagnosed with ACS following radiotherapy from our hospital-based cohort of early breast cancer patients aged <71 years, treated 1970-2009. Cardiovascular disease incidence and cause of death were acquired through questionnaires to general practitioners and cardiologists. Internal mammary chain (IMC) irradiation delivers the highest heart doses in breast cancer radiotherapy. Hence, we compared ACS prognosis between patients treated with/without IMC-irradiation. ACS prognosis was assessed through cardiac death, death due to ACS and cardiovascular disease incidence, using multivariable Cox proportional hazard models and by estimating cumulative incidence. RESULTS: In total, 62% of patients with ACS had received IMC-irradiation and 38% did not (median age at ACS diagnosis, 67 years). Median time between breast cancer and ACS was 15 years. After ACS, ten-year cumulative risk of cardiac death was 35% for patients who had IMC-irradiation (95% confidence interval [95%CI] 29-41) compared to 24% (95%CI 17-31) for patients without IMC-irradiation (p = 0.04). After correction for confounders, IMC-irradiation remained associated with a less favourable prognosis of ACS compared to no IMC-irradiation (hazard ratio cardiac death = 1.7, 95%CI 1.1-2.5). CONCLUSION: Our results suggest that radiotherapy, in case of substantial heart doses,may worsen ACS prognosis. This is an important, novel finding that may impact upon the risk-based care for breast cancer survivors with ACS.
引用
- Boekel NB, Boekel LY, Buddeke J, et al. Prognosis of acute coronary syndromes after radiotherapy for breast cancer. Radiother Oncol. 2020. PMID: 32146256. doi:10.1016/j.radonc.2020.02.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。